| abemaciclib based treatment | cyclin inhibitor | palbociclib based treatment | ribociclib based treatment |
| abemaciclib plus aromatase inhibitor | abemaciclib plus endocrine therapy | abemaciclib plus fulvestrant | dalpiciclib plus fulvestrant | palbociclib plus endocrine therapy | palbociclib plus fulvestrant | palbociclib plus letrozole | ribociclib plus endocrine therapy | ribociclib plus fulvestrant | ribociclib plus letrozole |
| es-BC - HR positive - (neo)adjuvant (NA) 2 | | | | | | | | | | |
| es-BC - HR-positive - 1st line (L1) 1 | | | | | | | | | | |
| la/mBC - HR positive 2 | | | | | | | | | | |
| la/mBC - HR positive - (neo)adjuvant (NA) 3 | | | | | | | | | | |
| la/mBC - HR positive - NA - PIK3CA mutant | | | | | | | | | | |
| la/mBC - HR-positive - 1st line (L1) 13 | | | | | | | | | | |
| la/mBC - HR positive - L1 - PIK3CA mutant 1 | | | | | | | | | | |
| la/mBC - HR-positive - 2nd line (L2) 20 | | | | | | | | | | |
| la/mBC - HR positive - L2 - all population 1 | | | | | | | | | | |
| la/mBC - HR positive - L2 - PIK3CA mutant 1 | | | | | | | | | | |